We are live on ! Find out more
ALNA

Allena Pharmaceuticals
ALNA

Delisted

ALNA was delisted on the 7th of September, 2022.

Back to rankings

26 hedge funds and large institutions have $39.5M invested in Allena Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

26% less funds holding

Funds holding: 35 → 26 (-9)

34% less capital invested

Capital invested by funds: $59.8M → $39.5M (-$20.3M)

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

Holders
26
Holders Change
-9
Holders Change %
-25.71%
% of All Funds
0.51%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
6
Increased
7
Reduced
6
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$1.48M
2
WVP
Worth Venture Partners
New Jersey
+$802K
3
SFM
Sphera Funds Management
Israel
+$801K
4
Renaissance Technologies
Renaissance Technologies
New York
+$379K
5
BCM
Bridgeway Capital Management
Texas
+$321K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$2.94M
2
PHS
PFM Health Sciences
California
-$1.92M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.35M
4
PA
Perceptive Advisors
New York
-$521K
5
JP Morgan Chase
JP Morgan Chase
New York
-$223K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
$169 -$4.26K -1,297 -95%
PHS
27
PFM Health Sciences
California
– -$1.92M -486,978 Closed
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
– -$1.35M -343,574 Closed
PA
29
Perceptive Advisors
New York
– -$521K -132,300 Closed
JP Morgan Chase
30
JP Morgan Chase
New York
– -$223K -56,579 Closed
Bank of New York Mellon
31
Bank of New York Mellon
New York
– -$75K -19,096 Closed
PP
32
Paloma Partners
Connecticut
– -$67K -17,113 Closed
LI
33
LVZ Inc
Michigan
– -$66K -16,735 Closed
Bank of America
34
Bank of America
North Carolina
– -$59K -14,854 Closed
RJFSA
35
Raymond James Financial Services Advisors
Florida
– -$43K -10,850 Closed
Acadian Asset Management
36
Acadian Asset Management
Massachusetts
– -$37K -9,345 Closed
Barclays
37
Barclays
United Kingdom
– -$32K -8,224 Closed
UBS Group
38
UBS Group
Switzerland
– -$13K -3,258 Closed
Victory Capital Management
39
Victory Capital Management
Texas
– -$7K -1,815 Closed
Citigroup
40
Citigroup
New York
– -$5K -1,307 Closed
PAM
41
Panagora Asset Management
Massachusetts
– -$3K -777 Closed
1
2

ALNA Hedge Fund Activity: Q4 2019 in Review

26 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q4 2019, worth a combined $39.5M — down 34% from $59.8M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ALNA and 6 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Deutsche Bank, opening a new position worth an estimated $1.48M. The largest seller was Morgan Stanley, cutting an estimated $2.94M.

  • 26 institutional investors held Allena Pharmaceuticals (ALNA) as of Q4 2019, down from 35 in Q3 2019.
  • Funds reported $39.5M of Allena Pharmaceuticals stock for Q4 2019, down 34% quarter-over-quarter.
  • 6 funds opened new Allena Pharmaceuticals positions in Q4 2019 and 15 closed out, a net change of -9 holders.
  • The largest Allena Pharmaceuticals buyer in Q4 2019 was Deutsche Bank, an estimated $1.48M added.
  • The largest Allena Pharmaceuticals seller in Q4 2019 was Morgan Stanley, an estimated $2.94M sold.

Based on aggregated 13F filings for Q4 2019.